iRhythm Technologies Inc Stock News

Irhythm Technologies Inc (NASDAQ:IRTC) CEO Kevin M. King sold 4,218 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $80.00, for a tot

CELLECT BIOTECH/S (NASDAQ:APOP) and Irhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their

Franklin Resources Inc. cut its holdings in shares of Irhythm Technologies Inc (NASDAQ:IRTC) by 34.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commi

Sector ETF report for XHE

Sector ETF report for XHE

Irhythm Technologies Inc (NASDAQ:IRTC) EVP David A. Vort sold 7,440 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $97.29, for a total

Charles Schwab Investment Management Inc. increased its holdings in Irhythm Technologies Inc (NASDAQ:IRTC) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securiti

We note that the iRhythm Technologies, Inc. (NASDAQ:IRTC) Independent Director, Ralph Snyderman, recently sold US$64k...

Irhythm Technologies Inc (NASDAQ:IRTC) Director Ralph Snyderman sold 650 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average pric

Irhythm Technologies Inc (NASDAQ:IRTC)’s stock price dropped 5.6% during trading on Friday after an insider sold shares in the company. The company traded as low as $93.03 and last traded at $95.72,

Barclays PLC increased its holdings in Irhythm Technologies Inc (NASDAQ:IRTC) by 2,201.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exc

Irhythm Technologies Inc (NASDAQ:IRTC) has received an average recommendation of “Buy” from the eleven research firms that are currently covering the company, Marketbeat reports. One analyst has r

10X Genomics (NASDAQ:TXG) initiated with Buy rating and $95 (23% upside) price target at Guggenheim.Abbott (NYSE:ABT) initiated with Buy rating at Citigroup. Shares down 1% premarket.Alcon (NYSE:ALC

Element Science was valued at $230 million when it scored its Series A round in August, more than 10 times its previous valuation. The San Francisco medical device and information technology company i

Press Release Element Science, an innovative health technology company pioneering a next-generation digital wearable platform focused on high-risk cardiovascular patients transitioning from the hospit